PMID- 16683887
OWN - NLM
STAT- MEDLINE
DCOM- 20060525
LR  - 20210527
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 130
IP  - 5
DP  - 2006 May
TI  - Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ 
      hybridization and multiplex and monoplex polymerase chain reactions.
PG  - 691-8
AB  - CONTEXT: Previous reports suggest that the human epidermal growth factor 2 
      (HER-2/neu) receptor may be overexpressed in osteosarcoma. OBJECTIVE: To 
      determine whether osteosarcomas have amplifications of the HER-2/neu gene. 
      DESIGN: We studied a series of osteosarcomas by fluorescence in situ 
      hybridization (FISH) and by 2 real-time polymerase chain reaction assays that 
      measure the amount of HER-2/neu DNA relative to a control gene. The HER-2/ neu 
      monoplex and multiplex assays were capable of identifying those cases of breast 
      cancer that were known to overexpress HER-2/neu as assessed by FISH. We initially 
      studied 21 cases of osteosarcoma by FISH analysis (using a technique that 
      included a probe for chromosome 17), 11 of which had their HER-2/neu gene 
      amplification status previously reported. RESULTS: None of these osteosarcoma 
      cases showed HER-2/neu amplification by our FISH analysis and subsequent 
      quantitative (multiplex) polymerase chain reaction. Apparent expression of 
      HER-2/neu protein was observed in several of the cases but the immunoreactivity 
      was localized to the cytoplasm and was not membranous in character. An additional 
      35 osteosarcoma specimens were subjected to monoplex polymerase chain reaction 
      analysis, and amplifiable DNA was recovered from 19 specimens (54%). None of 
      these samples had HER-2/neu amplification by monoplex PCR analysis and only one 
      case had membranous immunoreactivity graded as 1+. CONCLUSION: Although a small 
      subset of osteosarcomas had weak noncircumferential membranous immunoreactivity 
      for HER-2/neu protein, no osteosarcomas demonstrated positive (2+ or 3+) 
      immunoreactivity for HER-2/ neu protein and none showed HER-2/neu gene 
      amplification by either FISH or polymerase chain reaction.
FAU - Willmore-Payne, Carlynn
AU  - Willmore-Payne C
AD  - Department of Pathology, University of Utah Health Sciences Center, Salt Lake 
      City, UT 84132, USA.
FAU - Holden, Joseph A
AU  - Holden JA
FAU - Zhou, Holly
AU  - Zhou H
FAU - Gupta, Dilip
AU  - Gupta D
FAU - Hirschowitz, Sharon
AU  - Hirschowitz S
FAU - Wittwer, Carl T
AU  - Wittwer CT
FAU - Layfield, Lester J
AU  - Layfield LJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (DNA Primers)
RN  - 0 (DNA Probes)
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Bone Neoplasms/*genetics/metabolism/pathology
MH  - DNA Primers/chemistry
MH  - DNA Probes/chemistry
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Osteosarcoma/*genetics/metabolism/pathology
MH  - Polymerase Chain Reaction/*methods
MH  - Receptor, ErbB-2/*genetics/metabolism
EDAT- 2006/05/11 09:00
MHDA- 2006/05/26 09:00
CRDT- 2006/05/11 09:00
PHST- 2006/05/11 09:00 [pubmed]
PHST- 2006/05/26 09:00 [medline]
PHST- 2006/05/11 09:00 [entrez]
AID - OA5467 [pii]
AID - 10.5858/2006-130-691-EONGSI [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2006 May;130(5):691-8. doi: 10.5858/2006-130-691-EONGSI.